Compare Enphase Energy Inc (ENPH) vs Viatris Inc (VTRS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Enphase Energy Inc vs Viatris Inc — how do they compare? Enphase Energy Inc trades at $33.19 (market cap $4.35B), while Viatris Inc trades at $17.49 (market cap $20.03B). The key difference: Viatris Inc is far larger — about 4.6× Enphase Energy Inc's market cap, and Viatris Inc pays a 2.75% dividend while Enphase Energy Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Enphase Energy Inc for 72 Days and Viatris Inc for 57 Days on average.
| ENPH | VTRS | |
|---|---|---|
Market Cap | $4.35B | $20.03B |
Volume | 5,068,595 | 14,109,977 |
Sector | Energy | Health |
52-Week High | $72.33 | $18.27 |
52-Week Low | $26.12 | $9.74 |
Typical Hold Time | 72 Days | 57 Days |
Enterprise Value | $3.99B | $32.15B |
Dividend Yield | — | 2.75% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Enphase Energy (ENPH) trades at $33.50, down 1.21% with bearish technical signals and mixed earnings performance. The stock shows declining revenue from $2.3B in 2023 to $1.47B in 2025, though net margins improved to 10.09%. Recent developments include IQ Meter Collar approvals and solid-state transformer production for AI data centers, providing potential growth catalysts amid solar sector volatility.
Outlook remains cautious with analyst consensus at $42.90 (28% upside) but recent earnings misses and high borrowing costs for solar projects pose near-term risks. The stock offers exposure to energy technology innovation but faces competitive pressure and macroeconomic headwinds affecting renewable energy demand.
Viatris (VTRS) trades at $17.49, down 0.29% with a bullish technical signal supported by moving averages and oversold RSI levels. The company shows consistent earnings beats with Q2 2026 EPS of $0.69 exceeding expectations, while maintaining strong operational cash flow of $2.32B in 2025. Recent developments include FDA approval for WAKIX in Japan and continued recognition as a top employer.
Despite negative net margins, Viatris demonstrates improving cash flow trends and strategic portfolio optimization. The stock offers 27% upside to consensus price target of $22.17, though investors face risks from debt levels and competitive pressures in the generic drug market. Deleveraging progress and pipeline advancements support potential re-rating.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Enphase Energy Inc
Enphase Energy is a global energy technology company. The company delivers smart, easy-to-use solutions that manage solar generation, storage, and communication on one platform. The company's microinverter technology primarily serves the rooftop solar market and produces a fully integrated solar-plus-storage solution. Geographically, it derives a majority of revenue from the United States.
Read more on ENPH →About Viatris Inc
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →
